Banco Macro S.A.

BMA Q3 2025

Reported: 2025-12-02

Banco Macro reported a significant net loss of ARS 33.1 billion in Q3 2025, reflecting a sharp decline in profitability driven by increased loan loss provisions and decreased income across key segments.

Key takeaways

Net interest income decreased by 7% quarter-on-quarter to ARS 686.2 billion, primarily due to a spike in interest expenses.
Provisions for loan losses soared 45% from the prior quarter, totaling ARS 156.8 billion, indicating heightened credit risk.
Administrative expenses increased by 12% quarter-on-quarter to ARS 331.5 billion, impacted by rising employee benefits costs.

View recap

Hafnia Limited

HAFN Q3 2025

Reported: 2025-12-02

Hafnia reported a strong Q3 2025, achieving $150.5 million in adjusted EBITDA and a net profit of $91.5 million, driven by robust tanker market conditions and strategic fleet optimization.

Key takeaways

Adjusted EBITDA of $150.5 million and net profit of $91.5 million represent the company's best quarterly performance this year.
Successful sale of four older vessels as part of a fleet renewal strategy and a binding agreement to acquire 14.45% of TORM shares.
Sustained commitment to shareholders with an 80% payout ratio, translating to a cash dividend of $73.2 million or $0.1470 per share.
Improvement in net loan-to-value ratio from 24.1% to 20.5%, bolstered by strong operational cash flows and vessel market value uptick.
Continued strong demand for clean petroleum products aids in tight supply and favorable trading conditions amid significant regulatory sanctions impacting vessel availability.

View recap

Simulations Plus, Inc.

SLP Q4 2025

Reported: 2025-12-02

Simulations Plus delivered strong fiscal 2025 results with a 13% increase in total revenue, while navigating a challenging market landscape. A strategic transition to a unified operating model is set to enhance operational capacity and responsiveness.

Key takeaways

Revenue for the fourth quarter decreased 6% to $17.5 million, attributed to external market pressures.
Full-year adjusted EBITDA and EPS both increased by 8%, reflecting operational resilience despite significant industry headwinds.
The successful transition to a unified operating model positions the company for accelerated growth, capitalizing on the increasing adoption of biosimulation tools in R&D environments.
Customer engagement is improving, as evidenced by increased proposal activity and a strong 88% renewal rate for the fiscal year.
Continued investment in AI-driven solutions and cloud capabilities to enhance product offerings and support long-term demand in the biopharma sector.

View recap

Victrex plc

VCT.L Q4 2025

Reported: 2025-12-02

Victrex reported a challenging fiscal year 2025, with a 12% increase in sales volume but a 21% decline in underlying profit before tax, driven by currency impacts and weaker medical revenue performance.

Key takeaways

Sales volume reached 4,164 tonnes, reflecting robust demand from value-added resellers and the Energy & Industrial sectors.
Revenue growth was minimal at 1% to GBP 292.7 million, negatively impacted by currency fluctuations and a weaker medical spine segment.
Implemented a profit improvement plan targeting over GBP 10 million in savings, leveraging recent foundational investments in infrastructure and technology.
Operating cash conversion remained strong at 121%, supported by effective working capital management and reduced capital expenditures.
Outlook for FY 2026 anticipates solid progress on both revenue and profitability, indicating resilience despite ongoing challenges.

View recap

Earnings Recaps

Banco Macro S.A.

Hafnia Limited

Simulations Plus, Inc.

Victrex plc

Community

Earnings Recaps

Banco Macro S.A.

Hafnia Limited

Simulations Plus, Inc.

Victrex plc

Community

Trending This Week

Notifications